Breaking News Instant updates and real-time market news.

ESTA

Establishment Labs

$22.80

-0.4 (-1.72%)

, AGN

Allergan

$146.77

-1.53 (-1.03%)

08:43
12/19/18
12/19
08:43
12/19/18
08:43

Establishment may benefit from Allergan breast implant issue, says Jefferies

Jefferies analyst Raj Denhoy noted that Allergan's (AGN) CE mark for textured breast implants was not renewed and the products can no longer be distributed in the EU and other markets, which he believes could benefit Establishment Labs (ESTA) given its better surface technology. Allergan's textured share in EU is a $100M opportunity, even a portion of which would be significant for Establishment considering a $60M forecast for 2018 revenues, said Denhoy. He keeps a Buy rating and $35 price target on Establishment Labs shares.

ESTA

Establishment Labs

$22.80

-0.4 (-1.72%)

AGN

Allergan

$146.77

-1.53 (-1.03%)

  • 05

    Jan

ESTA Establishment Labs
$22.80

-0.4 (-1.72%)

08/13/18
JEFF
08/13/18
INITIATION
Target $35
JEFF
Buy
Jefferies starts Establishment Labs with Buy rating, $35 target
Jefferies analyst Raj Denhoy initiated coverage of Establishment Labs with a Buy rating and $35 price target. With its Motiva implant, the company has "reimagined breast augmentation," Denhoy tells investors in a research note. The analyst models for annual revenue growth of 30% over the next five years. However, should the clinical data continue to be as good as the early results, the opportunity for Establishment Labs "to grow well beyond that is significant," Denhoy contends.
08/13/18
BTIG
08/13/18
INITIATION
Target $35
BTIG
Buy
Establishment Labs initiated with a Buy at BTIG
BTIG analyst Sean Lavin initiated Establishment Labs with a Buy rating and a price target of $35, saying he expects the company's Motiva portfolio to be a "channel disruptor" in the breast implant market given its "natural feel and impressive safety profile". The analyst expects Establishment Labs' "continued geographic expansion and momentum in Brazil" to produce above-average revenue growth in the near-term, while noting that the company's biggest risks are "competition and sustainability of exceptional outcomes".
08/14/18
08/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hudbay Minerals (HBM) reinstated with a Neutral at BofA/Merrill. 2. Establishment Labs (ESTA) initiated with a Buy at BTIG and Jefferies and an Outperform at Cowen. 3. Yext (YEXT) initiated with a Buy at SunTrust. 4. Akebia (AKBA) initiated with an Outperform at Raymond James. 5. Replimune Group (REPL) was initiated with an Outperform at Leerink and BMO Capital as well as an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/18
BTIG
11/14/18
NO CHANGE
Target $40
BTIG
Buy
Establishment Labs price target raised to $40 from $35 at BTIG
BTIG analyst Sean Lavin raised his price target on Establishment Labs to $40 and kept his Buy rating after its Q3 revenue came in well above expectations. The analyst states the top-line strength was driven by the momentum in Brazil and the Scandinavian countries, with the company having accessed nearly a quarter of the former's plastic surgeons in just over a year of market presence. Lavin adds that Establishment Labs' gross margin of 62%, driven by manufacturing leverage and higher average selling price, was also a positive, even though he believes that the company can do even better over the coming "couple of quarters".
AGN Allergan
$146.77

-1.53 (-1.03%)

11/30/18
RBCM
11/30/18
NO CHANGE
Target $220
RBCM
Outperform
RBC shares investor frustration, but sees 'unlocked value' in Allergan
In a research note last night titled "Is it time for bold change at AGN? Investor frustration is high but value remains," RBC Capital analyst Randall Stanicky said he continues to see "significant unlocked value" in shares of Allergan. The analyst added that like many investors, he's frustrated. While it's easy to point to pipeline opportunity, after three years of underperformance, debate around whether it is time for bigger change has justifiably returned, Stanicky wrote. The reality, according to the analyst, is that both Allergan's pipeline and the potential push for a break-up "add optionality" on an "already compelling valuation." Amidst this backdrop, the analyst believes the focus on next week's conference update will be high. While there has been some positive evolution, like the board refresh and reduced focus on big acquisitions, the company's overall strategy is "unchanged and premised on investor appetite to own a platform comprised of various therapeutic assets combined via historical specialty pharma consolidation," says Stanicky. He believes investor frustration "is justified as is a sense of urgency to address performance." Nonetheless, the analyst's view on Allergan remains unchanged. He sees "attractive pipeline opportunity" with the greater value creation opportunity coming from a "more aggressive platform revisit/break-up." Both the potential for a strategic revisit and pipeline add to the stock's attractive risk/reward, contends Stanicky. Divesting Women's Health and/or Anti-infectives may seem incremental, but it would still be a "positive first step while a reversal in course would likely be a catalyst for greater investor frustration," Stanicky adds. The analyst kept an Outperform rating on Allergan with a $220 price target. The stock in midday trading is unchanged at $155.24.
12/03/18
PIPR
12/03/18
NO CHANGE
Target $65
PIPR
Overweight
Piper says buy Biohaven 'aggressively' after 'impressive' data
Biohaven Pharmaceutical (BHVN) this morning reported "impressive" topline data from the Phase III trial testing the Zydis orally dissolving tablet formulation of rimegepant, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The study not only achieved statistical significance on both co-primary endpoints, "but surprisingly" also demonstrated an "incredibly rapid" 15 minute onset of action, says the analyst. Further, he notes that Biohaven reported pooled safety data from what is now three Phase III rimegepant studies and that the candidate "continues to be safe and well tolerated" with no signal of liver toxicity. Van Buren believes the new data "definitely makes" rimegepant a superior product to Allergan's (AGN) ubrogepant and the "best-in-class" oral calcitonin gene-related peptide. He reiterates an Overweight rating on Biohaven with a $65 price target and recommends that investors buy the stock "aggressively."
12/12/18
STFL
12/12/18
NO CHANGE
Target $35
STFL
Buy
Synergy's GI assets 'fit squarely' into Bausch Health GI wheelhouse, says Stifel
Stifel analyst Annabel Samimy notes that Bausch Health (BHC) entered into a "stalking horse" bid to acquire through bankruptcy proceedings substantially all of Synergy Pharmaceutical's (SGYP) GI assets, which includes rights to Trulance/plecanotide, dolcanatide and its intellectual property. While still subject to competitive bids, these assets "fit squarely" into Bausch Health's GI wheelhouse, which would immediately leverage the company's sales and payer infrastructure and physician relationships in the space, the analyst contends. Though competitive with Allergan's (AGN) Linzess, Bausch Health has proven a strong player in the GI space and she thinks it is exactly the presence needed to optimize/maximize sales of Trulance, with its strong efficacy and tolerability profile. Samimy reiterates a Buy rating and $35 price target on Bausch Health's shares.
12/17/18
PIPR
12/17/18
NO CHANGE
Target $164
PIPR
Overweight
Shire approval another potential headwind for Allergan, says Piper Jaffray
Piper Jaffray analyst David Amsellem views Shire's (SHPG) FDA approval Friday for its 5-HT4 receptor agonist Motegrity in chronic idiopathic constipation as another potential headwind for Allergan's (AGN) Linzess. The headwind is not necessarily in terms of pressure on volumes, but more in terms of the potential for a more challenging payer environment, Amsellem tells investors in a research note. The analyst remains cautious on Allergan given his concerns regarding the trajectory of the commercial portfolio as well as its pipeline. Amsellem reiterates a Neutral rating on the stock with a $164 price target.

TODAY'S FREE FLY STORIES

01:50
11/19/19
11/19
01:50
11/19/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

EFC

Ellington Financial

$18.79

0.01 (0.05%)

20:29
11/18/19
11/18
20:29
11/18/19
20:29
Syndicate
Ellington Financial 4.2M share Spot Secondary priced at $18.20 »

The stock priced below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HD

Home Depot

$238.98

1.64 (0.69%)

, MDT

Medtronic

$111.25

-0.86 (-0.77%)

20:25
11/18/19
11/18
20:25
11/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HD

Home Depot

$238.98

1.64 (0.69%)

MDT

Medtronic

$111.25

-0.86 (-0.77%)

TJX

TJX

$59.54

-0.25 (-0.42%)

TDG

TransDigm

$568.32

9.81 (1.76%)

ARMK

Aramark

$43.90

0.25 (0.57%)

KSS

Kohl's

$58.39

-0.71 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 05

    Dec

  • 11

    Dec

ACY

AeroCentury

$3.31

-0.66 (-16.62%)

20:01
11/18/19
11/18
20:01
11/18/19
20:01
Hot Stocks
AeroCentury sells one Bombardier CRJ900 to Aeronautical Support International »

AeroCentury announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$6.02

-0.14 (-2.27%)

19:29
11/18/19
11/18
19:29
11/18/19
19:29
Hot Stocks
Myovant Sciences up over 11% after announcing Phase 3 Study conference call »

Shares of Myovant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$29.95

-0.04 (-0.13%)

18:47
11/18/19
11/18
18:47
11/18/19
18:47
Hot Stocks
Invitation Homes CEO sells 70K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

, LUV

Southwest

$57.77

-0.03 (-0.05%)

18:44
11/18/19
11/18
18:44
11/18/19
18:44
Periodicals
Boeing to provide Southwest board with 737 MAX update this week, Reuters says »

Boeing (BA) this week…

BA

Boeing

$369.50

-2.05 (-0.55%)

LUV

Southwest

$57.77

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GBDC

Golub Capital

$17.79

0.045 (0.25%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Upgrade
Golub Capital rating change at Keefe Bruyette »

Golub Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GM

General Motors

$36.62

-0.25 (-0.68%)

, TM

Toyota

$143.53

-0.76 (-0.53%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Periodicals
CA to halt purchase of GM, Toyota, Fiat Chrysler vehicles, Reuters reports »

The state of California…

GM

General Motors

$36.62

-0.25 (-0.68%)

TM

Toyota

$143.53

-0.76 (-0.53%)

FCAU

Fiat Chrysler

$15.63

-0.39 (-2.43%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

LEVI

Levi Strauss

$17.06

-0.115 (-0.67%)

18:31
11/18/19
11/18
18:31
11/18/19
18:31
Hot Stocks
Levi Strauss CEO: I believe in the importance of innovation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.17

0.07 (0.16%)

18:17
11/18/19
11/18
18:17
11/18/19
18:17
Periodicals
Cisco sues former employees over claims of trade secret theft, Bloomberg says »

Cisco is suing two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ABBV

AbbVie

$88.71

0.07 (0.08%)

18:09
11/18/19
11/18
18:09
11/18/19
18:09
Hot Stocks
AbbVie treatment of myelofibrosis granted FDA orphan status »

AbbVie's navitoclax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PRQR

ProQR Therapeutics

$6.27

-0.64 (-9.26%)

18:06
11/18/19
11/18
18:06
11/18/19
18:06
Hot Stocks
ProQR Therapeutics treatment of retinal dystrophy in P23H granted orphan status »

ProQR Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:04
11/18/19
11/18
18:04
11/18/19
18:04
Earnings
Bilibili sees Q4 revenue RMB1.93B-RMB1.98B »

Q4 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com sees Q4 revenue up 12%-15% in RMB terms »

Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Hot Stocks
Bilibili reports average MAUs reached 127.9M in Q3 »

Average monthly active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com reports Q3 adjusted EPS 96c, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:01
11/18/19
11/18
18:01
11/18/19
18:01
Earnings
Bilibili reports Q3 adjusted EPS (15c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

DDOG

Datadog

$40.36

-0.33 (-0.81%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:56
11/18/19
11/18
17:56
11/18/19
17:56
Hot Stocks
Datadog announces support for AWS CloudFormation Registry and CLI »

Datadog (DDOG) announced…

DDOG

Datadog

$40.36

-0.33 (-0.81%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

17:55
11/18/19
11/18
17:55
11/18/19
17:55
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

GVA

Granite Construction

$26.50

-0.6 (-2.21%)

17:54
11/18/19
11/18
17:54
11/18/19
17:54
Hot Stocks
Granite Construction awarded $14M airfield improvement project in California »

Granite announced it was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$44.46

-1.37 (-2.99%)

, MSFT

Microsoft

$150.35

0.4 (0.27%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Initiation
Zscaler, Microsoft initiated at DA Davidson »

Zscaler initiated with a…

ZS

Zscaler

$44.46

-1.37 (-2.99%)

MSFT

Microsoft

$150.35

0.4 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 16

    Dec

OKTA

Okta

$121.21

3.76 (3.20%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Upgrade
Okta rating change at DA Davidson »

Okta pullback represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

PANW

Palo Alto Networks

$248.50

1.465 (0.59%)

17:48
11/18/19
11/18
17:48
11/18/19
17:48
Initiation
Palo Alto Networks initiated at DA Davidson »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.